

February 28, 2012

Dear clients and colleagues,

Based on data from the American Pet Products Association (APPA), pet spending has seen robust growth even in periods of economic slowdowns. Over the last 11 years spending per household with a pet has grown at 4.4% although during the last recession owners have been less likely to take their pets in for routine check-ups and emergency care. With the economic recovery well on the way in the US and with favorable demographics, we believe that Vet industry growth will reaccelerate.

We recently initiated a position in VCA Antech (WOOF US) to participate in this important part of the economy.

Business Overview

VCA Antech was founded in 1986 with the purchase of an animal hospital in Los Angeles. Today, the company operates 575 hospitals in 41 States and Canada and 55 laboratories in the US and Canada providing diagnostic services to over 14 000 independent hospitals.

Stock Data

WOOF US, www.vcaantech.com \$22.40. Market cap US\$1.95B, P/E (12/2012): 15.6x, ev/ebitda (12/2012) 8.5x, no dividend, Debt/EBITDA: 2.2x, Ebitda margin: 19%, annual sales growth: Last 4 years: 6.5%, Next 4 years: 12%, annual profit growth next 4 years: 18%.

Target Market


The market for veterinary services in the US and Canada is around \$30 Billion and growing at 4% per year. It is highly resilient. A study done by the American Pet Association revealed that:

- 94% of pet owners believe their pet has human personality traits;
- 93% of pet owners would risk their own life for their pet;
- 86% include their pet in holiday celebrations;
- 67% take their pet on vacations with them;
- 65% sing or dance for their pet;
- 53% spend more on their pet than three years ago;
- 52% prepare special meals for their pet.

This report is provided solely for informational purposes and nothing in this document constitutes an offer or a solicitation of an offer to purchase any security. This report has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient and does not constitute a representation that any investment strategy is suitable or appropriate to a recipient's individual circumstances. Global Alpha Capital Management Ltd. (Global Alpha) in no case directly or implicitly guarantees the future value of securities mentioned in this document. The opinions expressed herein are based on Global Alpha's analysis as at the date of this report, and any opinions, projections or estimates may be changed without notice. Global Alpha, its affiliates, directors, officers and employees may buy, sell or hold a position in securities of a company(ies) mentioned herein. The particulars contained herein were obtained from sources, which Global believes to be reliable but Global Alpha makes no representation or warranty as to the completeness or accuracy of the information contained herein and accepts no responsibility or liability for loss or damage arising from the receipt or use of this document or its contents.

Performance figures are stated in Canadian dollars and are net of trading costs and gross of operating expenses and management fees. Further information about the Global Small Cap Composite is available by contacting the firm. Global Alpha Capital Management Ltd. (Global Alpha) claims compliance with the Global Investment Performance Standards (GIPS ®) and has prepared and presented this report in compliance with the GIPS. Global Alpha has not been independently verified.

Figure 35 – VCA Antech Overview



Source: Company Reports

Competitive Advantages

With over 575 hospitals and 55 labs, the company has the leading industry position. It is a logical choice for veterinarians who want to partner with the company, allowing them to concentrate on animal care while leaving VCA to manage the administrative and marketing side of the business. It is also a preferred buyer for vets wanting to sell their practice.

The industry is characterized by high fixed costs. The company has the advantage that it can leverage this fixed cost base with its scale and vertical integration.

Competition

There are over 24 000 animal hospitals in the US and Canada. There are also two other laboratory companies. The market, however, is stable and rational.

Growth Strategy

Since its inception, the company has been the industry consolidator. Already the largest player but with less than 3% of the market in hospitals, the company has a large opportunity.

This report is provided solely for informational purposes and nothing in this document constitutes an offer or a solicitation of an offer to purchase any security. This report has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient and does not constitute a representation that any investment strategy is suitable or appropriate to a recipient's individual circumstances. Global Alpha Capital Management Ltd. (Global Alpha) in no case directly or implicitly guarantees the future value of securities mentioned in this document. The opinions expressed herein are based on Global Alpha's analysis as at the date of this report, and any opinions, projections or estimates may be changed without notice. Global Alpha, its affiliates, directors, officers and employees may buy, sell or hold a position in securities of a company(ies) mentioned herein. The particulars contained herein were obtained from sources, which Global believes to be reliable but Global Alpha makes no representation or warranty as to the completeness or accuracy of the information contained herein and accepts no responsibility or liability for loss or damage arising from the receipt or use of this document or its contents.

Performance figures are stated in Canadian dollars and are net of trading costs and gross of operating expenses and management fees. Further information about the Global Small Cap Composite is available by contacting the firm. Global Alpha Capital Management Ltd. (Global Alpha) claims compliance with the Global Investment Performance Standards (GIPS®) and has prepared and presented this report in compliance with the GIPS. Global Alpha has not been independently verified.

In addition, in the last few years, the company has made investments and acquisitions in the software and online space for vets and pet owners. Today, its web site www.vetstreet.com is the most used site in the space and similar to WebMD.

Management


The Founder Bon Antin is CEO, President and Chairman; his co-founder, Arthur Antin, is COO; while Neil Tauber, another co-founder, is Senior VP of Development. The CFO, Tomas Fuller, joined in 1988 and has been CFO since November 1990. Together they own 5% of the company and have increased their ownership in the last six months.

Why BUY Now?

Industry growth is re-accelerating with the improving US economy.

VCA, after years of investments in the business, has just returned to same-hospital sales growth. In a high fixed cost model, earnings growth should be quite strong.

Chart 1: Pet adoptions at Animal Welfare Organizations (% growth yoy)




Source: PetHealth, BofA Merrill Lynch Global Research

This report is provided solely for informational purposes and nothing in this document constitutes an offer or a solicitation of an offer to purchase any security. This report has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient and does not constitute a representation that any investment strategy is suitable or appropriate to a recipient's individual circumstances. Global Alpha Capital Management Ltd. (Global Alpha) in no case directly or implicitly guarantees the future value of securities mentioned in this document. The opinions expressed herein are based on Global Alpha's analysis as at the date of this report, and any opinions, projections or estimates may be changed without notice. Global Alpha, its affiliates, directors, officers and employees may buy, sell or hold a position in securities of a company(ies) mentioned herein. The particulars contained herein were obtained from sources, which Global believes to be reliable but Global Alpha makes no representation or warranty as to the completeness or accuracy of the information contained herein and accepts no responsibility or liability for loss or damage arising from the receipt or use of this document or its contents.

Performance figures are stated in Canadian dollars and are net of trading costs and gross of operating expenses and management fees. Further information about the Global Small Cap Composite is available by contacting the firm. Global Alpha Capital Management Ltd. (Global Alpha) claims compliance with the Global Investment Performance Standards (GIPS ®) and has prepared and presented this report in compliance with the GIPS. Global Alpha has not been independently verified.

Chart 2: YTD Rx prescribed by veterinarians



Source: IMS HEALTH, BofA Merrill Lynch Global Research

Risks

- The economy remains fragile.
- The company carries debt and has substantial goodwill on the balance sheet.
- Two new laboratory companies may be aggressive in winning share and cutting prices.

Valuation

Target price = US\$35, using DCF model at growth rate of 12% for the next 8 years, 5% at maturity, risk premium of 8%, and payout at maturity of 50%.

Have a nice week.

The Global Alpha Team

This report is provided solely for informational purposes and nothing in this document constitutes an offer or a solicitation of an offer to purchase any security. This report has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient and does not constitute a representation that any investment strategy is suitable or appropriate to a recipient's individual circumstances. Global Alpha Capital Management Ltd. (Global Alpha) in no case directly or implicitly guarantees the future value of securities mentioned in this document. The opinions expressed herein are based on Global Alpha's analysis as at the date of this report, and any opinions, projections or estimates may be changed without notice. Global Alpha, its affiliates, directors, officers and employees may buy, sell or hold a position in securities of a company(ies) mentioned herein. The particulars contained herein were obtained from sources, which Global believes to be reliable but Global Alpha makes no representation or warranty as to the completeness or accuracy of the information contained herein and accepts no responsibility or liability for loss or damage arising from the receipt or use of this document or its contents.

Performance figures are stated in Canadian dollars and are net of trading costs and gross of operating expenses and management fees. Further information about the Global Small Cap Composite is available by contacting the firm. Global Alpha Capital Management Ltd. (Global Alpha) claims compliance with the Global Investment Performance Standards (GIPS®) and has prepared and presented this report in compliance with the GIPS. Global Alpha has not been independently verified.